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012.10.0Abstract The rapid translation from bench to bedside that has been seen in the application of
regenerative medicine to cardiology has led to exciting new advances in our understanding of some
of the fundamental mechanisms related to human biology. The ﬁrst generation of cells used in phase
I–II trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with
the goal of producing a cell based therapeutics that can change the outcome of cardiac disease. First
generation cell therapy appears to have addressed safety concerns as well as showing ‘activity’ in
numerous published meta-analyses. With the knowledge gained to date, the ﬁeld is moving towards
the next generation of cells––the ‘engineered’ cell––that has been developed to display a phenotype
that will further enhance the myocardial repair/salvage process. This almanac review covers the lat-
est basic research that may soon have application to humans as well as the results of the latest clin-
ical trials.
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disease
Cell therapy is one of the most important ‘new horizons’ in car-
diovascular disease. It offers new opportunities to develop ther-
apeutics that could revolutionise the way we treat patients and
a ﬁeld of research that combines an increased understanding of
the pathophysiology of the cardiovascular disease with some of
the most basic biological concepts involved in embryology. The
resultant growth of preclinical research in the cardiovascular
system and the rapid translation into humans has led to beneﬁts
for human biology as a whole. The ﬁeld is rapidly advancing;
here, we present key developments in the last 2 years. In order
to reﬂect the synergy between basic and translational research,
this review is therefore divided into two sections.
2. Basic science update on cell therapy in cardiovascular disease
2.1. New models enhancing our understanding of regeneration
zebraﬁsh
There is a long history of research on amphibian heart regener-
ation with the most adopted model the zebraﬁsh given its sub-
stantial regenerative capacity and amenability to genetic
manipulation. The zebraﬁsh heart fully regenerates after the sur-
gical amputation of the cardiac apex: an injury that corresponds
to a loss of approximately 20% of the total ventricular mass.1
Initial experiments suggested that undifferentiated progenitor
cells were the principal source of regenerating cardiomyocytes
in zebraﬁsh; however, two recent gene mapping studies clearly
demonstrate that pre-existing committed cardiomyocytes are in-
stead themain source.2,3 These two groups independently gener-
ated transgenic zebraﬁsh in which the cardiomyocyte-speciﬁc
cmlc2 (also known as myl7) promoter drives the expression of
tamoxifen-inducible Cre recombinase. These animals were
crossed with a reporter line in which Cre-mediated excision of
a loxP-ﬂanked stop sequence induces constitutive expression
of green ﬂuorescent protein (GFP). In the offspring of this cross,
all pre-existing cardiomyocytes and their progeny were induced
to express GFP by tamoxifen treatment. Therefore, if the regen-erated myocardium was derived from undifferentiated progeni-
tor cells, the new ventricular apex should be GFP. Instead,
both groups found that the vast majority of the newly regener-
ated cardiomyocytes were GFP+, suggesting that the heart
regeneration in zebraﬁsh is principally mediated by the prolifer-
ation of pre-existing cardiomyocytes. This is contrary to the pre-
viously held belief that the generation of new cardiomyocytes
from stem cells was the underlying aetiology.
2.2. Mice versus zebraﬁsh
Although they lack the regenerative capacity of the zebraﬁsh
heart, postnatal mammalian hearts also undergo a degree of
cardiomyocyte renewal during normal ageing and disease. Re-
cently, a study4 showed that the differences between mamma-
lian and ﬁsh hearts may not necessarily apply early in
development. Using approaches from the zebraﬁsh model,
the authors resected the left ventricular (LV) apex of 1-day-
old neonatal mice and observed a brisk regenerative response
similar to that in the adult zebraﬁsh. By 3 weeks after injury,
the defect had been replaced by normal myocardial tissue,
which showed normal contractile function by 8 weeks. Genetic
fate-mapping studies indicated that this regeneration was med-
iated by the proliferation of pre-existing cardiomyocytes, again
as in the zebraﬁsh. Notably, this regenerative capacity was not
observed in 7-day-old mice, suggesting that its loss may coin-
cide with cardiomyocyte binucleation and reduced cell-cycle
activity. Nonetheless, this study indicates that zebraﬁsh-like
regenerative mechanisms are latent in mammalian hearts. It
also provides a genetically tractable model for dissecting the
blocks to these mechanisms in the mammalian adult.2.3. Alternative sources of cardiomyocytes: new concepts and
advanced understanding
2.3.1. Fibroblasts as source of cardiomyocytes
It has recently been demonstrated that ﬁbroblasts in infarcts
could potentially be reprogrammed directly to cardiomyocytes.
Fifteen years ago, researchers showed that ﬁbroblasts could be
differentiated into skeletal muscle in vitro or in the injured heart
Almanac 2012, cell therapy in cardiovascular disease: The national society journals present selected research 15by overexpressing the gene encoding themyogenic transcription
factor, MyoD. However, despite extensive work, no compara-
ble master gene for cardiac muscle was found, and interest in
reprogramming waned. Spurred by the discovery of induced
pluripotent stem cells (iPSCs), scientists have now returned to
this ﬁeld, using combinations of transcription factors to reacti-
vate core transcriptional networks of desired cell types. In the
last 2 years, two groups have made progress to this goal. The
ﬁrst group5 screened a total of 14 cardiac transcription factors
ﬁnding that a speciﬁc combination of three transcription fac-
tors, Gata4, Mef2c and Tbx5, was sufﬁcient to generate func-
tional beating cardiomyocytes directly from mouse postnatal
cardiac or dermal ﬁbroblasts and that the induced cardiomyo-
cytes were globally reprogrammed to adopt a cardiomyocyte-
like gene expression proﬁle. These factors activated the trans-
gene in 20% of ﬁbroblasts of which approximately 4% of the
cells expressed endogenous sarcomeric proteins such as cardiac
troponin T, with 1% showing functional properties such as
spontaneous beating. Thus, most of the cells were only partially
reprogrammed, although their global gene expression patterns
had shifted markedly from ﬁbroblast to cardiomyocyte.
The second group6 used a different method of reprogram-
ming mouse embryonic ﬁbroblasts to cardiomyocytes. They
used the ‘Yamanaka factors’––OCT4 (also known as POU5F1),
SOX2, KLF4 and c-MYC––to initiate reprogramming, but then
blocked signalling through the JAK––STAT pathway, which is
required for pluripotency in the mouse, and added the cardio-
genic factor BMP4. These modiﬁcations yielded a minimal gen-
eration of iPSCs, but instead activated the cardiac progenitor
programme and, within 2 weeks, generated substantial numbers
of beating colonies. By 18 days after induction, approximately
40% of the cells expressed cardiac troponin T. It should be
noted that this study used mouse embryonic ﬁbroblasts,
whereas Leda et al.5 principally used postnatal mouse cardiac
ﬁbroblasts. Reprogramming the scar-forming ﬁbroblast to a
cardiomyocyte is appealing, particularly if it can be done di-
rectly in the infarct. To succeed clinically, we need to know
how normal these reprogrammed cardiomyocytes are, and the
process will have to be much more efﬁcient and transgene-free.
2.4. Induced pluripotent stem cells
A recent report in this journal drew attention to the great
promise of iPSC (reprogrammed somatic cells) as a renewable
source of autologous cells.7 These cells were ﬁrst discovered
only 5 years ago by Takahashi and Yamanaka8 following the
introduction of genes into adult mouse cells reprogramming
them to resemble embryonic stem (ES) cells. Given that the
DNA of such cells is identical to that of the patient, it has been
assumed that they would not be attacked by the immune sys-
tem although their immunogenicity has not been vigorously
examined. However, a study9 published in Nature in
2011showed that in a mouse transplantation model, some
iPS cells are indeed immunogenic, raising concerns about their
therapeutic use. This study examined the immunogenicity of
mouse iPS cells, using a teratoma-formation assay. They in-
jected iPS cells into mice that were either immune-compro-
mised or genetically matched with the donor cells. This
normally results in the formation of benign tumours called ter-
atomas, which consist of many types of differentiated cells.
The approach was validated using a line of genetically matched
(autologous) ES cells which gave rise to teratomas, whereas aline of unmatched ES cells was rejected before teratomas were
produced. The transplantation of autologous iPS cells derived
from foetal ﬁbroblasts into matched mice resulted in the rejec-
tion of teratomas, irrespective of the approach used to gener-
ate the IPS cells, indicating that, in this assay, matched iPS
cells are more immunogenic than matched ES cells.
The study also identiﬁed the antigens that may have caused
immune rejection of the iPS cells, discovering a group of nine
genes that were expressed at abnormally high levels. Inducing
the expression of three of these genes (Hormadl, Zgl6 and
Cyp3a11) in the non-immunogenic ES cells signiﬁcantly im-
paired the cells’ ability to form teratomas on transplantation
into genetically matched mice. This study provides more ques-
tions than answers with many limitations in relation in clinical
studies; however, it highlights that a great deal needs to be
understood about the mechanisms underlying cellular repro-
gramming and the inherent similarities and differences be-
tween ES cells and iPS cells.
2.5. Adjunctive therapies to improve stem cell differentiation
As a related spin-off to cell therapy, two new approaches to
cardiac repair have been reported.
2.6. Thymosin b4
One of the most exciting developments in regenerative medicine
over the past 2 years has been the identiﬁcation of ‘bona ﬁde
source of myocardial progenitors’ (epicardial derived cells)10
which can be induced by thymosin b4 to differentiate into
cardiomyocytes. This landmark study by Smart et al.11 pro-
vides a major step forward in identifying a viable source of
stem/progenitor cells that could contribute to new muscle after
ischaemic heart disease and acute myocardial infarction (AMI).
They demonstrated that in a mouse model the adult heart con-
tains a resident progenitor cell population, which has the poten-
tial to become terminally differentiated cardiomyocytes after
MI. Progenitor cells were primed with a peptide called thymo-
sin b4 which induced embryonic reprogramming resulting in
the mobilisation of this population and subsequent differentia-
tion to give rise to de novo cardiomyocytes. Following experi-
mentally induced MI, these cells were shown to migrate to the
site of injury and then differentiate without any evidence of cel-
lular fusion into structurally and functionally active cardio-
myocytes. These cardiomyocytes showed evidence of gap junc-
tion formation with adjacent cells, synchronous calcium tran-
sients and the formation of operational contractile apparatus.
Despite a low overall fraction of these cells being present at
the site of injury and a relatively poor overall efﬁciency of dif-
ferentiation, serial MRI scans revealed signiﬁcant improve-
ments in ejection fraction, cardiac volumes and scar size in
comparison with sham treated animals. The pretreatment with
thymosin b4 was crucial to these effects and may suggest a new
strategy for promoting myocardial repair in humans.
2.7. MicroRNAs
MicroRNAs (small non-coding RNAs) play a critical role in
differentiation and self-renewal of pluripotent stem cells, as
well as in the differentiation of cardiovascular lineage cells.
As a result, microRNAs have emerged as potential modulators
of stem cell differentiation; speciﬁcally, miR-1 has been re-
16 D.A. Jones et al.ported to play an integral role in the regulation of cardiac mus-
cle progenitor cell differentiation. A study published in 201112
looked to take this one step further and assessed whether the
overexpression of miR-1 in ES cells (miR-1-ES cells) enhances
cardiac myocyte differentiation following transplantation into
the infarcted myocardium. In this study, mice models of MI
had miR-1-ES cells, ES cells or culture medium (control) trans-
planted into the border zone of the infarcted heart. Overex-
pression of miR-1 in transplanted ES cells protected host
myocardium from MI-induced apoptosis through activation
of p-AKT and inhibition of caspase-3, phosphatase and tensin
homologue, and superoxide production. A signiﬁcant reduc-
tion in interstitial and vascular ﬁbrosis was quantiﬁed in
miR-1-ES cells compared with control MI. Finally, mice
receiving miR-1-ES cells had signiﬁcantly improved heart
function compared with respective controls. This would sug-
gest that miR-1 drives cardiac myocyte differentiation from
transplanted ES cells and inhibits apoptosis post-MI; however,
importantly with respect to ﬁbrosis no statistical signiﬁcance
between miR-1-ES cell and ES cell groups was observed sug-
gesting further study in this area is needed. A review13 of the
current evidence for the role of microRNAs in stem/progenitor
cells and cardiovascular repair has recently been published.
3. Clinical update on cell therapy in cardiovascular disease
The translational path from preclinical observation to new
treatment development can take many years, even decades.
Ten years after the ﬁrst clinical application of stem cells in car-
diac disease,14 many questions regarding cell types and their
administration have been addressed and researchers are better
understanding this area of research and the challenges of trans-
lational medicine.
Although many candidate cell types for myocardial repair
exist, a pragmatic approach has been used in clinical trials which
have utilised autologous bone marrow mononuclear cells
(BMMNCs) and some of the component cell types found therein
(haematopoietic stem cells, mesenchymal stem cells (MSCs) and
endothelial progenitor cells) in the ﬁrst steps into the clinical set-
ting.15 Recent years have seen several phase I–II clinical trials of
BMMNC transplantation in cardiac disease which have demon-
strated safety and feasibility while reports of efﬁcacy, although
less consistent, have provided grounds for further investigation.4. Recent developments in the use of autologous bmmncs
The last 2 years have seen some of the larger trials examining
BMMNCs in the setting of AMI reporting long-term results
conﬁrming safety to 3–5 years. Reassuringly, recent meta-anal-
yses to look at these studies have again conﬁrmed a small but
important ‘activity’ of cell therapy in improving various surro-
gate parameters of cardiac function.16,17
The ﬁrst randomised controlled trial of stem cell therapy in
AMI was the BOOST trial (BOne marrOw transfer to enhance
ST-elevation infarct regeneration) reporting a 6.7% increase in
global left ventricular ejection fraction (LVEF) in the treatment
group compared with a 0.7% increase in the control group at
6 months; this was attributed to improved regional systolic wall
motion in the infarct zone.18 The 5-year follow-up data19
showed a decline in LVEF and increase in LV volumes in both
groups with no signiﬁcant difference in mortality or clinical endpoints between the groups. Interestingly, subgroup analyses
suggested that in more severe infarction, deﬁned as greater
transmurality, cell therapy conferred a signiﬁcant beneﬁt in
LVEF and LV dimension compared with control.
The Reinfusion of Enriched Progenitor cells And Infarct
Remodeling in Acute Myocardial Infarction (REPAIR-AMI)
trial is the largest randomised controlled trial in stem cell ther-
apy for cardiac repair to date. The original study that enrolled
204 patients with AMI demonstrated a signiﬁcantly greater
improvement in absolute LVEF in patients treated with
BMMNCs compared with control at 4 months. As seen in
BOOST, the patients with larger infarcts derived the most ben-
eﬁt. Although not sufﬁciently powered for the purpose, this
was the ﬁrst large scale clinical endpoint data showing mortal-
ity and morbidity beneﬁt conferred by the intracoronary
administration of stem cells.20 This was borne out at 2 years
with signiﬁcant reductions in combined clinical end point
and increases in LV wall motion when assessed on MRI in
the patients who received BMMNCs.21 The 5-year follow-up
data, presented at the American Heart Association (AHA) Sci-
entiﬁc Sessions 2011,22 included 100 patients in each treatment
arm. While there was only a trend towards improvement in
mortality, there was a signiﬁcant reduction of the combined
end point of death, recurrence of MI and revascularisation
conferred by a single intracoronary infusion of cells.
Long-term follow-up data from 100 patients enrolled in the
Autologous Stem-cell Transplantation in Acute Myocardial
Infarction (ASTAMI) trial showed a signiﬁcant improvement
in exercise capacity in the treated cohort at 3 years, although
there was no signiﬁcant difference in LVEF between treatment
and placebo arms.23 The 5-year follow-up for the ‘BALANCE’
study (Clinical Beneﬁt and Long-Term Outcome After Intra-
coronary Autologous Bone Marrow Cell Transplantation in
Patients With Acute Myocardial Infarction) showed signiﬁcant
and sustained improvement in LV function and reduction in
mortality in 62 treated patients compared with 62 control pa-
tients. Although this suggests a signiﬁcant mortality beneﬁt, it
is noted that this study was non-randomised.24 Another large
trial (HEBE) consisting of 200 patients has also been published
recently25 showing no signiﬁcant improvement in the LV func-
tion in BMMNC treated patients compared with placebo up to
4 months; however, the long-term effects of cell therapy in this
study are yet to be reported.
The majority of these studies are in the context of cell
administration 5–8 days following AMI. There is still a need
to deﬁne the optimal time point for cell transfer relative to
ischaemic insult. It is conceivable that the improvement in
LV function and outcome seen inconsistently between trials
may be dependent on the timing of cell transfer as the postin-
farct myocardium will have a changing inﬂammatory milieu.
The later time point of 2–3 weeks post-AMI is addressed by
the recent LateTIME study.26 Here, the authors found that
in 87 patients randomised to either BMMNCs or control,
BMMNC treatment at the given time point did not improve
either global LVEF or regional wall motion at 6 months.
Although the likelihood is that days 5–7 are the optimal time
for delivery of cell therapy post-AMI, not all time points have
been investigated. The ongoing trials TIME27 and SWISS-
AMI28 aim to evaluate the timing of injection further. As
yet, the only time point that has not been considered is the very
early phase (<12 h post-revascularisation). The REGENER-
ATE-AMI clinical trial (EUDRACT 2007–002144––16) in
Almanac 2012, cell therapy in cardiovascular disease: The national society journals present selected research 17which BMMNCs are transferred approximately 6 h post-PCI
is over halfway through recruitment and will report in 2013.
There is now a need to better deﬁne those patients who will
beneﬁt from cell therapy. The results of the 5-year follow-up
from the BOOST and REPAIR-AMI trials suggest that if ejec-
tion fraction is used as a surrogate end point, while the overall
effect may be modest for all-comers, subgroups with a large
functional deﬁcit at baseline do experience clinically meaning-
ful increments in LVEF. This is further substantiated by the
FINCELL substudy29 in which 78 patients received either
BMMNCs or placebo post-thrombolysis and PCI for AMI.
Here, a signiﬁcantly greater BMMNC associated improvement
in LV function was observed in patients with baseline LVEF
below the median for the group.
Despite the heterogeneity of trial results described, the
largest meta-analysis to date comprising 1765 patients and
33 randomised controlled trials demonstrates a modest but
signiﬁcant improvement in LVEF of 2.87% in short-term
follow-up, with sustained LVEF improvement of 3.75% after
follow-up over 1 year16 suggesting that adjunctive stem cell
treatment in AMI offers an improvement over conventional
therapy. These effects while modest are comparable with those
seen in landmark studies of primary angioplasty, ACE inhibi-
tors and b-blockers30 and suggest that a similar additional
mortality beneﬁt may be achieved. The majority of trials in this
ﬁeld to date use LVEF as a surrogate clinical end point with
little understanding of how this parameter relates to outcome.
Recently, two trials of BMMNCs in AMI have been pub-
lished attempting to explore alternative surrogate end points.
The aim of the ‘‘Bone Marrow in Acute Myocardial Infarction
(BONAMI)’’ was to assess the effect on myocardial variability
at 3 months recruiting 101 patients with poor LV function
post-AMI to receive BMMNCs or placebo. Myocardial viabil-
ity was signiﬁcantly improved in the treated group compared
with control.31 In another trial,32 LVEF was assessed along-
side myocardial perfusion in a similar patient cohort up to
12 months. A small improvement in myocardial perfusion
was observed in the BMMNC group compared with control;
there was however a signiﬁcantly lower incidence of combined
major adverse cardiac events in the treatment group, highlight-
ing again an ill-deﬁned relationship between potential surro-
gate markers and hard clinical outcome measures.
One of the most important developments to date is the
move from phase II to phase III clinical trials. The majority
of the current clinical trials have been designed to assess safety
and feasibility only, and being underpowered to assess efﬁcacy
of the technology use surrogate markers such as LVEF to as-
sess activity. In order to address this issue, the EU funding
programme recently awarded a consortium composed of 17
clinical centres across Europe €6 million to design and conduct
the deﬁnitive outcome study of BMMNC in AMI (BAMI;
http://www.bami-fp7.eu). BAMI will enrol 3000 patients with
the primary end point as all-cause mortality making it one of
the most exciting developments in the ﬁeld for several years.
The study will be reported in 5 years.
4.1. Cell therapy for chronic LV disease
The STAR-heart study is the largest reported experience of
BMMNCs in ischaemic heart failure and reported its
5-year follow-up data in 2010.33 The non-randomised study
originally recruited 391 patients with an LVEF of 35% or lesswho were offered intracoronary administration of autologous
BMMNCs. In all, 191 patients received cell therapy and 200
patients received best medical treatment alone. At 5-year
follow-up, there were signiﬁcant improvements in LVEF, con-
tractility, oxygen uptake and exercise tolerance in patients
treated with BMMNCs associated with perhaps more interest-
ingly a signiﬁcantly lower death rate than the control group.
This requires conﬁrmation in a double-blinded randomised
study. The FOCUS-HF trial34 is a randomised controlled trial
of 30 patients designed to evaluate the effects of transendocar-
dial delivery of BMMNCs in patients with chronic ischaemic
heart failure with no option for further revascularisation. At
6 months, although there was no difference in LVEF between
the treated and placebo groups, cell therapy was found to sig-
niﬁcantly improve symptoms and quality of life scores and in
subgroup analysis oxygen uptake in patients who were
60 years and younger. Another recent study35 assessed the ef-
fect of cell therapy as an adjunct to bypass surgery (coronary
artery bypass graft (CABG)) in patients with ischaemic heart
failure undergoing CABG. An impressive increase in LVEF
and reduction in LV dimensions in the BMMNC group were
reported at 6-month follow-up.
Long-term data from the ﬁrst randomised controlled trial of
BMMNCs in dilated cardiomyopathy (Autologous Bone marrow
Cells inDilated cardiomyopathy (ABCD) trial)were reported in20
1 0.36 In the 41 patients followed to 3 years, there was a signiﬁcant
improvement in LVEF in the treatment group, greater in patients
with the NewYork Heart Association (NYHA) class 3 symptoms
compared withNYHA class 4 suggesting improvement in patients
was greater in those with less severely damaged myocardium.
There was also an associated symptomatic improvement but no
mortality beneﬁtwas shown.Trials ofBMMNCs innon-ischaemic
cardiomyopathy are ongoing.
4.2. Translation of other cell types into the clinical setting
Another major development in the last 2 years has been the
move towards clinical translation of different cell populations
and a search for the optimal cell type for cardiac repair with a
number of ﬁrst-in-human trials.
Circulating/mobilised haemopoietic stem cells identiﬁed
most commonly by markers CD34 and CD133 have been
investigated as potential candidate populations in cardiac re-
pair. These cell populations can either be fractionated from
BMMNC or mobilised into the circulation using pharmaco-
logical agents such as Granulocyte colony stimulating factor
(G-CSF). CD34 cells contain more endothelial lineage deter-
mined cells and have been previously evaluated in both AMI
and refractory angina. The Autologous Cellular Therapy
CD34 in Chronic Myocardial Ischemia (ACT-CMI) investiga-
tors have recently reported on a large phase II trial evaluating
intramyocardial injection of low and high dose autologous
peripherally mobilised CD34 cell therapy against placebo in
167 patients with refractory angina. There was found to be a
signiﬁcant improvement in angina frequency and exercise tol-
erance in the low dose group compared with placebo at 6
and 12 months. There was also an increased mortality in the
placebo arm.37 In contrast, Chih et al. report that despite
mobilisation of CD34 and CD34/CD133 cells using G-CSF,
no improvement in angina or myocardial perfusion was
observed in patients with chronic Ischaemic heart disease
(IHD)38 Again, this discrepancy in the ﬁndings from these
18 D.A. Jones et al.studies suggests that a careful consideration to the method of
delivery should be given and that intramyocardial delivery
may be more effective in this type of patients.
MSCs are able to release a large range of cardioprotec-
tive paracrine factors and transdifferentiate into a number
of cell types that are involved in cardiac repair and are there-
fore increasingly being used in clinical trials which have
shown promising results. Another advantage of MSCs is
their logistical ease of access via bone marrow and adipose
tissue.
The 6 month results of the ﬁrst-in-human randomised con-
trolled 14 patient trial of autologous adipose tissue derived
stem and regenerative cells (ADRCs) for AMI (the Adipose-
derived stem cells in the treatment of patients with ST-eleva-
tion myocardial Infarction (APOLLO) trial) have recently
been reported.39 All patients received either cell therapy or pla-
cebo within 24 h of primary PCI. These were ﬁrst MI patients
with an LVEF between 35% and 50%. At 6 months, there was
a signiﬁcant improvement in myocardial scar formation and
perfusion defect, near signiﬁcant reduction in infarct size and
improvement in estimated ejection fraction with cell therapy
compared with control, and the treatment proved safe. The
18 month data were presented at the 2011 International Sym-
posium on Stem Cell Therapy & Cardiovascular Innovation
and showed sustained beneﬁts. The next step, a larger study
called ADVANCE, enrolling 375 patients will give greater
statistical power. Eighteen month results for a similar ﬁrst-
in-human trial of ARDCs for ischaemic heart failure, PRE-
CISE, although not yet published, have been presented at
the AHA Scientiﬁc Sessions 2010.40 Here, 27 patients were ran-
domised to receive transendocardial ADRCs or placebo. Re-
sults at 6 months showed a signiﬁcant reduction in infarct
size in the treatment group relative to the controls but with
no difference in LVEF. Up to 18 months, cell therapy was
found to be safe with no difference in adverse outcomes be-
tween the two groups and found to signiﬁcantly improve both
NYHA and Canadian cardiovascular society (CCS) class
symptoms, metabolic equivalents and peak oxygen consump-
tion, in the treatment group.
Allogeneic as opposed to autologous MSCs have also re-
cently been evaluated as a potential novel therapeutic strategy
allowing for ‘off-the-shelf’ logistical ease. MSCs are able to
evade immune detection meaning immunosuppression is not
required for these patients. The ﬁrst-in-human phase I ran-
domised controlled study comparing allogeneic MSCs with
placebo in the setting of ﬁrst AMI and LV dysfunction en-
rolled 53 patients.41 Importantly, the study demonstrated no
difference in adverse events, rehospitalisation or arrhythmia
between the groups. At 18 months, the treatment group con-
ferred signiﬁcant improvement in LVEF relative to controls.
The preliminary results of a phase II randomised controlled
trial assessing allogeneic MSCs in the setting of ischaemic
heart failure were presented at the AHA Scientiﬁc Sessions
2011.22 The study consisted of 60 patients with a 12 month fol-
low-up period and conﬁrmed safety of the technology. While
there was no difference in LVEF between the two groups, there
was a signiﬁcantly lower incidence of major adverse cardiac
events, mortality and symptoms in the treated group support-
ing the concept of LVEF not being a useful surrogate marker
for outcome.
The attractive opportunity to exploit cardiac stem cells
(CSC) which are capable of regrowing healthy heart tissuewas realised with the discovery that the adult heart contains
its own reservoir of progenitor cells. There are two main
CSC populations that have been described, the c-kit + popu-
lation and cardio-sphere-derived cells, which are a natural
mix of heart derived cell subpopulations including c-kit+/
CD90- and cardiac MSCs c-kit-/CD90. Although it is uncer-
tain as to whether these will prove advantageous over other
stem cell types, particularly if they act in a paracrine manner,
both populations have been studied in the clinical setting.
The recently published SCIPIO trial (Cardiac stem cells in
patients with ischaemic cardiomyopathy) is a ﬁrst-in-human
phase I trial assessing the value of c-kit + CSCs in ischaemic
heart failure post-CABG.42 Here, autologous atrial appendage
c-kit + cells are isolated and expanded at the time of CABG
and re-infused 3–4 months after surgery. Importantly, there
was no difference in the adverse event rate between treatment
and control arms. At 8 months, there was a signiﬁcant
improvement in infarct size and LVEF in treated patients.
The CADUCEUS trial (cardiosphere-derived autologous stem
cells to reverse ventricular dysfunction) assessed the impact of
intracoronary infusion of autologous cardiosphere-derived
cells harvested from endomyocardial biopsies in patients 2–
3 months post-AMI in a phase I clinical trial.43 Here, LVEF
was signiﬁcantly improved at 12 months compared with con-
trols and there was a major reduction in scar mass on Cardiac
magnetic resonance imaging (CMR) in the treated but not the
control group. There was no difference in adverse outcome be-
tween the groups. Importantly, this is one of the ﬁrst trials of
cell therapy to suggest that the beneﬁts seen in relation to myo-
cardial repair are explained by a regenerative process. The re-
sults of a phase II trial will be eagerly awaited.
Although the ultimate goal of cell therapy is to restore car-
diac function and thereby improve quality of life and survival,
the mechanism by which this is achieved using cell therapy
continues to remain a topic of debate depending on the cell
type used. This area of research has nonetheless led to a better
understanding of how cells can in vitro be made to differenti-
ate into a phenotype that may improve cardiac repair. The ﬁrst
results of this approach in humans have recently been pub-
lished. In the C-Cure trial, the investigators have driven the
differentiation of BMMNCs into lineage-speciﬁc cardiac pro-
genitor cells using cardiogenesis proteins before cell transfer
via the trans-endocardial route44 to 45 patients with ischaemic
heart failure. At 6 month follow-up, there was signiﬁcant
improvement in LVEF and reduction of LV volumes as well
as signiﬁcant symptomatic improvement evidenced by the
6 min walk test in the treated group compared with the control
group. There were no signiﬁcant differences in adverse out-
come. The second phase of this trial is ongoing.5. Summary
Cell therapy research offers the prospect of a completely new
therapeutic approach in cardiology. The last 2 years have seen
a systematic move from phase I to phase II clinical trials using
established cell types together with the emergence of new cell
types in phase I studies that have only become feasible due
to the research that has been driven by the early translation
into humans. For the pragmatic approach of bone marrow
derived cell therapy, recent meta-analysis again conﬁrms the
potential for beneﬁt and this will now be addressed in a phase
Almanac 2012, cell therapy in cardiovascular disease: The national society journals present selected research 19III outcome study that will also standardise the technique of
cell processing and administration. Other cell types will need
to follow a similar path of investigation and no doubt the trials
of bone marrow derived cells will set the standards by which
different cell types and techniques will be judged.
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